A

Allogene Therapeutics
D

ALLO

2.20000
USD
0.09
(4.27%)
Market Closed
Volume
37,072
EPS
-1
Div Yield
-
P/E
-1
Market Cap
461,278,600
News

Title: Allogene Therapeutics

Sector: Healthcare
Industry: Biotechnology
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research anddevelopment efforts.